A. P. Chernova
Research Subjects
A. P. Chernova has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Alexey A. Tryakin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - Anastasia B. Rays
Moscow Multidisciplinary Clinical Center “Kommunarka”, Moscow Healthcare Department, 108814 Moscow, Russia
2 shared publications - D. A. Barsova
N. P. Napalkov Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)
2 shared publications - Daniil Stroyakovskiy
Moscow City Oncology Hospital No. 62
2 shared publications E. N. Kulikova
Noyabrsk Central City Hospital
2 shared publications- Fedor Vladimirovich Moiseenko
Saint Petersburg Clinical Research and Practical Center for Specialized Types of Medical Care (Oncologic)
2 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (4) , 363-374
Obinutuzumab-Based Regimens in the First-Line Therapy for Follicular Lymphoma: Data from Real-World Clinical Practice in 41 Medical Institutions
AIM. To assess the efficacy and safety of combined obinutuzumab-based regimens in the first-line therapy for follicular lymphoma (FL) in real-world clinical practice. MATERIALS & METHODS. This retrospective multicenter study enrolled 279 newly diagnosed FL patients treated with obinutuzumab in combination with chemotherapy at 41 medical institutions in Russia from 2018 to 2026. The median age of patients was 49.2 years (range 30–83 years), 60.6 % of them were women. Obinutuzumab-based regimens were predominantly administered to patients with stage III/IV (86.4 %), advanced tumor spread (60.2 %), and often with intraabdominal location (76.3 %). More than 1/3 of patients had extranodal lesions (41.9 %) and bulky tumors (34.8 %). According to FLIPI score, there were 74.9 % of patients with intermediate and poor prognosis. More than half of the patients (54.4 %) received anthracycline-based G-CHOP regimen as initial therapy, GB was administered to 30.1 % of patients. Maintenance therapy with obinutuzumab was used in 72.8 % of cases. RESULTS. Overall response to therapy was achieved in 95.6 % of patients, the rate of complete metabolic response was 91.1 %. Adverse events of any grade were observed in 51.8 % of patients, grade ≥ 3 was identified in 29 % (primarily neutropenia and infectious complications). With the median follow-up of 16.3 months, disease progression or relapse were diagnosed in 21 (7.5 %) patients, histological transformation into diffuse large B-cell lymphoma was reported after 6 out of 14 biopsies performed at the stage of FL relapse. The 2-year progression-free survival was 89.6 %, and the 2-year overall survival was 98 %. CONCLUSION. The results of this study confirm high efficacy of obinutuzumab in the first-line therapy for FL patients with prognostically unfavorable characteristics of tumor. Overall and complete metabolic response rates are consistent with the international data. The administration of obinutuzumab-based regimens provide significant therapeutic control of the disease and confirm the reproducibility of the data from clinical studies in real-world healthcare practice.
- 1 October 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (4) , 363-374
Open AccessObinutuzumab-Based Regimens in the First-Line Therapy for Follicular Lymphoma: Data from Real-World Clinical Practice in 41 Medical Institutions
AIM. To assess the efficacy and safety of combined obinutuzumab-based regimens in the first-line therapy for follicular lymphoma (FL) in real-world clinical practice. MATERIALS & METHODS. This retrospective multicenter study enrolled 279 newly diagnosed FL patients treated with obinutuzumab in combination with chemotherapy at 41 medical institutions in Russia from 2018 to 2026. The median age of patients was 49.2 years (range 30–83 years), 60.6 % of them were women. Obinutuzumab-based regimens were predominantly administered to patients with stage III/IV (86.4 %), advanced tumor spread (60.2 %), and often with intraabdominal location (76.3 %). More than 1/3 of patients had extranodal lesions (41.9 %) and bulky tumors (34.8 %). According to FLIPI score, there were 74.9 % of patients with intermediate and poor prognosis. More than half of the patients (54.4 %) received anthracycline-based G-CHOP regimen as initial therapy, GB was administered to 30.1 % of patients. Maintenance therapy with obinutuzumab was used in 72.8 % of cases. RESULTS. Overall response to therapy was achieved in 95.6 % of patients, the rate of complete metabolic response was 91.1 %. Adverse events of any grade were observed in 51.8 % of patients, grade ≥ 3 was identified in 29 % (primarily neutropenia and infectious complications). With the median follow-up of 16.3 months, disease progression or relapse were diagnosed in 21 (7.5 %) patients, histological transformation into diffuse large B-cell lymphoma was reported after 6 out of 14 biopsies performed at the stage of FL relapse. The 2-year progression-free survival was 89.6 %, and the 2-year overall survival was 98 %. CONCLUSION. The results of this study confirm high efficacy of obinutuzumab in the first-line therapy for FL patients with prognostically unfavorable characteristics of tumor. Overall and complete metabolic response rates are consistent with the international data. The administration of obinutuzumab-based regimens provide significant therapeutic control of the disease and confirm the reproducibility of the data from clinical studies in real-world healthcare practice.
- 23 June 2026
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 13 (2) , 47-66
Potential of comprehensive somatic profiling tumor tissue for a personalized approach to treatment selection in various malignant neoplasms
Purpose of the study. Evaluation of the therapy optimization for patients with solid tumors using comprehensive genomic profiling (CGP). Patients and methods. The article presents the results of a study involving patients from the Yamalo-Nenets Autonomous Okrug with malignant neoplasms of various localizations: breast cancer (n = 4), colorectal cancer (n = 3), gastric cancer (n = 1), cervical cancer (n = 1), ovarian cancer (n = 1), and prostate cancer (n = 1). Molecular genetic testing was performed using the Sentis™ Cancer+Discovery Panel (BGI). Biological material included FFPE tumor tissue sections containing >20 % tumor cells. Next-generation sequencing (NGS) parameters were as follows: sequencing depth > 900× for tumor samples and >300× for matched control samples (venous blood); insertion size ~140–210 bp; Q30 > 80 %; target coverage > 90 %. The analysis included 689 genes, microsatellite instability (MSI), tumor mutational burden (TMB), and germline pathogenic variants. Results. Clinically significant somatic biomarkers were identified in 8 of 11 cases (72.7 %), enabling optimization of treatment strategies toward the most effective therapeutic approaches. In 5 of these 8 cases (62.5 %), treatment plan modification included the potential use of off-label therapy following approval by a multidisciplinary tumor board. Germline (inherited) variants were detected in 4 of 11 cases (36.4 %), indicating the need for genetic counseling and evaluation of relatives. Conclusion. The implementation of CGP in clinical practice expands the possibilities for a personalized approach to the treatment of patients with metastatic and progressive malignant neoplasms through the identification of additional potential biomarkers of sensitivity or resistance to targeted anticancer agents and immunotherapy. Further evaluation of CGP effectiveness in a larger patient cohort appears warranted.
- 23 June 2026
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 13 (2) , 47-66
Potential of comprehensive somatic profiling tumor tissue for a personalized approach to treatment selection in various malignant neoplasms
Purpose of the study. Evaluation of the therapy optimization for patients with solid tumors using comprehensive genomic profiling (CGP). Patients and methods. The article presents the results of a study involving patients from the Yamalo-Nenets Autonomous Okrug with malignant neoplasms of various localizations: breast cancer (n = 4), colorectal cancer (n = 3), gastric cancer (n = 1), cervical cancer (n = 1), ovarian cancer (n = 1), and prostate cancer (n = 1). Molecular genetic testing was performed using the Sentis™ Cancer+Discovery Panel (BGI). Biological material included FFPE tumor tissue sections containing >20 % tumor cells. Next-generation sequencing (NGS) parameters were as follows: sequencing depth > 900× for tumor samples and >300× for matched control samples (venous blood); insertion size ~140–210 bp; Q30 > 80 %; target coverage > 90 %. The analysis included 689 genes, microsatellite instability (MSI), tumor mutational burden (TMB), and germline pathogenic variants. Results. Clinically significant somatic biomarkers were identified in 8 of 11 cases (72.7 %), enabling optimization of treatment strategies toward the most effective therapeutic approaches. In 5 of these 8 cases (62.5 %), treatment plan modification included the potential use of off-label therapy following approval by a multidisciplinary tumor board. Germline (inherited) variants were detected in 4 of 11 cases (36.4 %), indicating the need for genetic counseling and evaluation of relatives. Conclusion. The implementation of CGP in clinical practice expands the possibilities for a personalized approach to the treatment of patients with metastatic and progressive malignant neoplasms through the identification of additional potential biomarkers of sensitivity or resistance to targeted anticancer agents and immunotherapy. Further evaluation of CGP effectiveness in a larger patient cohort appears warranted.
- Open Access
- 21 April 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (1) , 50-61
Choice of the 3rd and the 4th line therapy sequence in patients with metastatic colorectal cancer
Introduction : Treatment options in the third line for patients with metastatic colorectal cancer are limited in the Russian Federation to the multikinase inhibitor regorafenib and the strategy of re-administering previously effective chemo-targeted therapy (hereinafter referred to as chemotherapy re-challenge). Aim : To evaluate the efficacy and safety of regorafenib and chemotherapy re-challenge in later lines of therapy for metastatic colorectal cancer, and to identify patient subgroups deriving the greatest clinical benefit from the upfront choice of each approach. Materials and methods: A multicenter retrospective study was conducted (four oncology institutions in the Russian Federation, 2010–2021). A total of 218 patients with metastatic colorectal cancer after progression on fluoropyrimidines, oxaliplatin, and irinotecan were included; they received regorafenib or chemotherapy re-challenge in the 3rd and / or 4th line. All patients had 4‑th line of treatment. The primary endpoint was median progression-free survival in the 3rd line; secondary endpoints included median progression-free survival in the 4th line, median overall survival, and toxicity (CTCAE v5.0). Survival was analyzed using the Kaplan — Meier method with the logrank test; subgroup analyses were performed according to clinical and prognostic factors. Results : Chemotherapy re-challenge was administered to 121 patients (55.5 %) and regorafenib to 97 (44.5 %); median age was 63 and 62 years, respectively (p = 0.41). Median overall survival was higher with chemotherapy re-challenge: 19.05 months versus 13.6 months (HR = 0.60; 95 % CI 0.43–0.83; p < 0.01). Median progression-free survival in the 3rd line was also higher in the chemotherapy re-challenge group: 6.06 versus 3.02 months (HR = 0.58; 95 % CI 0.44–0.76; p < 0.01). In the 4th line, no statistically significant differences in median progression-free survival were observed: 3.7 vs 2.87 months (HR = 0.78; 95 % CI 0.59–1.04; p = 0.09). Subgroup analyses showed an overall survival and / or progression-free survival advantage for chemotherapy re-challenge across all prognostic groups. Chemotherapy re-challenge was associated with a more favorable toxicity profile. Dose reduction of regorafenib was required in approximately 40 % of patients, and treatment discontinuation due to toxicity occurred in 8–10 %. Conclusion : In a selected cohort of patients able to receive subsequent lines of therapy, third-line chemotherapy re-challenge was associated with longer overall survival and progression-free survival compared with regorafenib.
- 21 April 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (1) , 50-61
Open AccessChoice of the 3rd and the 4th line therapy sequence in patients with metastatic colorectal cancer
Introduction : Treatment options in the third line for patients with metastatic colorectal cancer are limited in the Russian Federation to the multikinase inhibitor regorafenib and the strategy of re-administering previously effective chemo-targeted therapy (hereinafter referred to as chemotherapy re-challenge). Aim : To evaluate the efficacy and safety of regorafenib and chemotherapy re-challenge in later lines of therapy for metastatic colorectal cancer, and to identify patient subgroups deriving the greatest clinical benefit from the upfront choice of each approach. Materials and methods: A multicenter retrospective study was conducted (four oncology institutions in the Russian Federation, 2010–2021). A total of 218 patients with metastatic colorectal cancer after progression on fluoropyrimidines, oxaliplatin, and irinotecan were included; they received regorafenib or chemotherapy re-challenge in the 3rd and / or 4th line. All patients had 4‑th line of treatment. The primary endpoint was median progression-free survival in the 3rd line; secondary endpoints included median progression-free survival in the 4th line, median overall survival, and toxicity (CTCAE v5.0). Survival was analyzed using the Kaplan — Meier method with the logrank test; subgroup analyses were performed according to clinical and prognostic factors. Results : Chemotherapy re-challenge was administered to 121 patients (55.5 %) and regorafenib to 97 (44.5 %); median age was 63 and 62 years, respectively (p = 0.41). Median overall survival was higher with chemotherapy re-challenge: 19.05 months versus 13.6 months (HR = 0.60; 95 % CI 0.43–0.83; p < 0.01). Median progression-free survival in the 3rd line was also higher in the chemotherapy re-challenge group: 6.06 versus 3.02 months (HR = 0.58; 95 % CI 0.44–0.76; p < 0.01). In the 4th line, no statistically significant differences in median progression-free survival were observed: 3.7 vs 2.87 months (HR = 0.78; 95 % CI 0.59–1.04; p = 0.09). Subgroup analyses showed an overall survival and / or progression-free survival advantage for chemotherapy re-challenge across all prognostic groups. Chemotherapy re-challenge was associated with a more favorable toxicity profile. Dose reduction of regorafenib was required in approximately 40 % of patients, and treatment discontinuation due to toxicity occurred in 8–10 %. Conclusion : In a selected cohort of patients able to receive subsequent lines of therapy, third-line chemotherapy re-challenge was associated with longer overall survival and progression-free survival compared with regorafenib.
- Open Access
- 21 April 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (1) , 33-48
Structure of germline pathogenic variants associated with hereditary cancer syndromes in patients with malignant neoplasms from the Yamalo-Nenets Autonomous Okrug based on whole-genome sequencing results
Introduction : Hereditary cancer syndromes (HCS) represent a group of genetically determined diseases where the risk of developing various types of tumors is significantly higher compared to the general population. Iden tifying germline pathogenic variants (PVs) associated with an increased risk of tumor formation is crucial for prevention, diagnosis, and treatment of patients. Scientific studies conducted on Russian patients with malignant neoplasms (MNs) will help to identify genetic markers of HCS that are specific to different ethnic groups and patient samples. Aim : To analyze the results of whole-genome sequencing (WGS) of 500 patients with MNs from the Yamalo-Nenets Autonomous Okrug (YNAO) and to identify germline variants associated with the development of HCS in oncology patients, along with a description of the structure and frequency of the genetic variants obtained. Methods : Since 2021, unique scientific projects aimed at identifying genetic variants associated with HCS have been implemented in YNAO using WGS. This study included 500 patients with MNs meeting at least one of the following criteria: 1) early age at onset of MN; 2) multiple primary MNs; 3) certain histological and immunohisto chemical characteristics of MNs; 4) a significant family cancer history. Whole-genome sequencing of DNA isolated from peripheral blood lymphocytes was performed. Results : WGS results demonstrated that 83 out of 500 patients with MNs were found to have PVs in genes associ ated with carcinogenesis, accounting for 16.6 %. This article presents the structure of the identified PVs in groups of patients with breast and ovarian cancers, patients with colorectal cancer and endometrial cancer, as well as in a heterogeneous group of patients with various tumor types. Conclusion : We have published the WGS results from YNAO for the first time and analyzed the structure of the obtained genetic variants in oncology patients. Research on the genetic characteristics of the patients from YNAO not only helps to identify patients at increased risk of developing cancer, providing them with preventive measures and effective treatment but also generates unique scientific information necessary for the development and adap tation of molecular genetic tests considering the sample’s peculiarities and international experience.
- 21 April 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (1) , 33-48
Open AccessStructure of germline pathogenic variants associated with hereditary cancer syndromes in patients with malignant neoplasms from the Yamalo-Nenets Autonomous Okrug based on whole-genome sequencing results
Introduction : Hereditary cancer syndromes (HCS) represent a group of genetically determined diseases where the risk of developing various types of tumors is significantly higher compared to the general population. Iden tifying germline pathogenic variants (PVs) associated with an increased risk of tumor formation is crucial for prevention, diagnosis, and treatment of patients. Scientific studies conducted on Russian patients with malignant neoplasms (MNs) will help to identify genetic markers of HCS that are specific to different ethnic groups and patient samples. Aim : To analyze the results of whole-genome sequencing (WGS) of 500 patients with MNs from the Yamalo-Nenets Autonomous Okrug (YNAO) and to identify germline variants associated with the development of HCS in oncology patients, along with a description of the structure and frequency of the genetic variants obtained. Methods : Since 2021, unique scientific projects aimed at identifying genetic variants associated with HCS have been implemented in YNAO using WGS. This study included 500 patients with MNs meeting at least one of the following criteria: 1) early age at onset of MN; 2) multiple primary MNs; 3) certain histological and immunohisto chemical characteristics of MNs; 4) a significant family cancer history. Whole-genome sequencing of DNA isolated from peripheral blood lymphocytes was performed. Results : WGS results demonstrated that 83 out of 500 patients with MNs were found to have PVs in genes associ ated with carcinogenesis, accounting for 16.6 %. This article presents the structure of the identified PVs in groups of patients with breast and ovarian cancers, patients with colorectal cancer and endometrial cancer, as well as in a heterogeneous group of patients with various tumor types. Conclusion : We have published the WGS results from YNAO for the first time and analyzed the structure of the obtained genetic variants in oncology patients. Research on the genetic characteristics of the patients from YNAO not only helps to identify patients at increased risk of developing cancer, providing them with preventive measures and effective treatment but also generates unique scientific information necessary for the development and adap tation of molecular genetic tests considering the sample’s peculiarities and international experience.
- Open Access
- 15 March 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (1)
Analysis of the efficacy and safety of regorafenib versus chemotherapy retreatment in 3rd line treatment of metastatic colorectal cancer
Introduction. Therapeutic options for 3rd-line treatment of metastatic colorectal cancer (mCRC) include chemotherapy retreatment with previously used regimens and regorafenib. Due to the lack of phase III prospective studies and conflicting retrospective results, we performed a comparative analysis of the efficacy and safety of chemotherapy ± targeted therapy retreatment versus regorafenib in a large patient cohort. Materials and methods. The study included mCRC patients from 4 oncology centers in the Russian Federation treated between 2010 and 2021 who received 3rd-line therapy either with chemotherapy ± targeted agents (epidermal growth factor receptor or vascular endothelial growth factor antibodies) (CTT group) or with regorafenib. The primary endpoint was 9-month overall survival (OS); secondary endpoints were progression-free survival (PFS), objective response rate (ORR) and toxicity. Univariable and multivariable analyses were conducted to identify prognostic factors. Results. A total of 334 patients were included. Median follow-up was 30.3 months (95 % confidence interval (CI) 26.0–34.5) in the CTT group and 23.8 months in the regorafenib group. The groups differed in several baseline characteristics: primary tumor resection was performed more frequently (76.1 % versus 67.6 %; p = 0.088) and ECOG 0 status was more common (25.2 % versus 14.2 %; p = 0.006) in the CTT group. Patients treated with regorafenib more frequently had elevated carcinoembryonic antigen ≥50 ng / mL (45.3 % versus 65.3 %; p 0.001) and indolent disease course ≥20 months (64.3 % versus 49.1 %; p = 0.005), while a «treatment-free interval» ≥6 months after oxaliplatin or irinotecan was observed less frequently (68.1 % versus 43.3 %; p 0.001). Chemotherapy retreatment demonstrated a statistically significant advantage in median OS (18.1 months versus 10.2 months; hazard ratio (HR) 0.51; 95 % CI 0.39–0.67; p 0.0001) and PFS (6.0 month versus 2.8 months; HR 0.54; 95 % CI 0.43–0.67; p 0.0001). ORR was 6.1 % in the CTT group compared to 0.6 % in the regorafenib group. In multivariable analysis, unfavorable prognostic factors were worse ECOG status (ECOG 1: HR 1.77; p = 0.002; ECOG 2: HR 2.56; p = 0.001), right-sided primary tumor location (HR 1.98; p 0.001), presence of ≥2 liver metastases (HR 1.52; p = 0.021), absence of radical resection of the primary tumor (HR 1.91, 95 % CI 1.32–2.78; p = 0.001), shorter interval between 1st-line and 3rd-line therapy (a longer course 20 months correlated with better prognosis: HR 1.38, 95 % CI 1.04–1.85; p = 0.028), and carcinoembryonic antigen ≥50 ng / mL (HR 1.38, 95 % CI 1.04–1.82; p = 0.026). Based on these factors, a prognostic model was created that identifies favorable (median OS 19.4 months), intermediate (median OS 13.0 months), and poor (median OS 6.6 months) risk groups. The C-index was 0.698 (standard error 0.02). Conclusion. Chemotherapy retreatment showed superiority over regorafenib in 3rd-line treatment of mCRC. Its higher efficacy was confirmed across all prognostic subgroups. Predictive analysis did not identify any subgroup with advantage from regorafenib therapy.
- 15 March 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (1)
Open AccessAnalysis of the efficacy and safety of regorafenib versus chemotherapy retreatment in 3rd line treatment of metastatic colorectal cancer
Introduction. Therapeutic options for 3rd-line treatment of metastatic colorectal cancer (mCRC) include chemotherapy retreatment with previously used regimens and regorafenib. Due to the lack of phase III prospective studies and conflicting retrospective results, we performed a comparative analysis of the efficacy and safety of chemotherapy ± targeted therapy retreatment versus regorafenib in a large patient cohort. Materials and methods. The study included mCRC patients from 4 oncology centers in the Russian Federation treated between 2010 and 2021 who received 3rd-line therapy either with chemotherapy ± targeted agents (epidermal growth factor receptor or vascular endothelial growth factor antibodies) (CTT group) or with regorafenib. The primary endpoint was 9-month overall survival (OS); secondary endpoints were progression-free survival (PFS), objective response rate (ORR) and toxicity. Univariable and multivariable analyses were conducted to identify prognostic factors. Results. A total of 334 patients were included. Median follow-up was 30.3 months (95 % confidence interval (CI) 26.0–34.5) in the CTT group and 23.8 months in the regorafenib group. The groups differed in several baseline characteristics: primary tumor resection was performed more frequently (76.1 % versus 67.6 %; p = 0.088) and ECOG 0 status was more common (25.2 % versus 14.2 %; p = 0.006) in the CTT group. Patients treated with regorafenib more frequently had elevated carcinoembryonic antigen ≥50 ng / mL (45.3 % versus 65.3 %; p 0.001) and indolent disease course ≥20 months (64.3 % versus 49.1 %; p = 0.005), while a «treatment-free interval» ≥6 months after oxaliplatin or irinotecan was observed less frequently (68.1 % versus 43.3 %; p 0.001). Chemotherapy retreatment demonstrated a statistically significant advantage in median OS (18.1 months versus 10.2 months; hazard ratio (HR) 0.51; 95 % CI 0.39–0.67; p 0.0001) and PFS (6.0 month versus 2.8 months; HR 0.54; 95 % CI 0.43–0.67; p 0.0001). ORR was 6.1 % in the CTT group compared to 0.6 % in the regorafenib group. In multivariable analysis, unfavorable prognostic factors were worse ECOG status (ECOG 1: HR 1.77; p = 0.002; ECOG 2: HR 2.56; p = 0.001), right-sided primary tumor location (HR 1.98; p 0.001), presence of ≥2 liver metastases (HR 1.52; p = 0.021), absence of radical resection of the primary tumor (HR 1.91, 95 % CI 1.32–2.78; p = 0.001), shorter interval between 1st-line and 3rd-line therapy (a longer course 20 months correlated with better prognosis: HR 1.38, 95 % CI 1.04–1.85; p = 0.028), and carcinoembryonic antigen ≥50 ng / mL (HR 1.38, 95 % CI 1.04–1.82; p = 0.026). Based on these factors, a prognostic model was created that identifies favorable (median OS 19.4 months), intermediate (median OS 13.0 months), and poor (median OS 6.6 months) risk groups. The C-index was 0.698 (standard error 0.02). Conclusion. Chemotherapy retreatment showed superiority over regorafenib in 3rd-line treatment of mCRC. Its higher efficacy was confirmed across all prognostic subgroups. Predictive analysis did not identify any subgroup with advantage from regorafenib therapy.